Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment ; volume:34 ; number:04 ; year:2013 ; pages:234-237
Indian journal of medical & paediatric oncology ; 34, Heft 04 (2013), 234-237
- Contributor
-
Hussein, Osama
Karen, Drumea
Zidan, Jamal
- DOI
-
10.4103/0971-5851.125233
- URN
-
urn:nbn:de:101:1-2021083013232568360087
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hussein, Osama
- Karen, Drumea
- Zidan, Jamal
Other Objects (12)
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study
TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Unusual Presentation of Differentiated Thyroid Cancer Metastasis
Poorly differentiated thyroid carcinoma : An underdiagnosed entity
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study
TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Unusual Presentation of Differentiated Thyroid Cancer Metastasis
Poorly differentiated thyroid carcinoma : An underdiagnosed entity
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study
TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer
Progressive Unilateral Proptosis and (18F) FDG-Avid Lesions Connoting Aggressive Disease in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Unusual Presentation of Differentiated Thyroid Cancer Metastasis
Poorly differentiated thyroid carcinoma : An underdiagnosed entity
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review